Abstract J
Introduction

Amitraz (N'-(2,4-dimethylphenyl)-N-[[(2,4-dimethylphenyl)-
. It is used, for example, in the treatment of demodicosis in dogs (3) . Amitraz has a relatively low melting point of 86-87~ and is unstable to acidic pH (2) (Figure 1 ). Toxicity of amitraz and other formamidine-type compounds to insects appear to involve activation of an octopamine-sensitive adenylate cyclase (4) , and metabolism of the drug typically involves generation of the highly active metabolite N-2,4-dimethylphenyl-N'-methylformamidine, known also as BTS-27271. Boophililus microplus larvae, for example, absorb amitraz rapidly but do not demonstrate large internal concentrations, owing to rapid cleavage to BTS-27271; the expected complementary cleavage product 2,4-dimethylformanilide was not produced in equivalent quantity, but large amounts of polar metabolites and 2,4-dimethylaniline were produced instead. Of the identified compounds, only amitraz and BTS-27271 displayed toxicity to larvae (5) . Amitraz applied to honeybee hives to prevent infestation with Varroajacobsoni could be extracted with a liquid-liquid regimen, followed by high-performance liquid chromatography (HPLC) with diode-array detection (DAD) (6) or by gas chromatography with nitrogen phosphorous detection (GC-NPD) and mass spectrometric (MS) confirmation (7) . Of seven acaricides detectable in honey and beeswax, amitraz was the least stable, degrading into BTS-beeswax and within 10 days in honey (8) . Amitraz has highly complex pharmacological and toxicological effects in mammals, and its use is specifically contraindicated in horses because of the not uncommon side-effect of severe colic when horses are exposed to this agent (9) . Intestinal immobility and stasis have also been demonstrated for amitraz and BTS-27271 in sheep up to 4 h post dose, and reversal with yohimbine indicates alpha-2 adrenergic agonist properties as most likely responsible (10, 11) . Nevertheless, in tropical countries such as Brazil, amitraz continues to be used for reasons of effectiveness and economy (12) . Behavioral and neurochemical studies of the effects of amitraz in rats showed that it decreased locomotion and increased immobility times in an open field, while increasing whole brain levels of noradrenaline and striatal levels of dopamine, possibly through inhibitory effects on monoamine oxidase (MAO) activity (13) . Studies in horses similarly indicate a dose-dependent decrease in locomotor activity for amitraz, with effects lasting up to 3 h following a 0.15 mg/kg dose. Yohimbine immediately reversed the sedative effects of amitraz here, as well, again indicating alpha-2 adrenergic agonist properties for this agent (14) . Measurement of additional physiological parameters such as hoof withdrawal reflex and skin twitch reflex indicate that amitraz presents a marked, long-lasting, and powerful sedative effect in horses, whereas antinociceptive effects occur only at the highest amitraz doses (12) .
In addition to its known effects on alpha-2 adrenergic receptors and on inhibition of MAO activity, amitraz has also been demonstrated to have a significant HI-histamine antagonist activity on isolated guinea-pig ileum. BTS-27271 had over threefold greater potency in this system, but the authors concluded that intestinal stasis was more likely due again to alpha-2 adrenergic agonist properties (10) . Selective activation of a specific subset of alpha-2D adrenergic receptors was considered responsible for observed effects on inhibition of insulin secretion and increase of glucagon secretion by both amitraz and BTS-27271 in a concentration-dependent manner in perfused rat pancreas (15) . Untoward effects of alpha-2 agonists such as xylazine include abortion, and Shin and Hsu (16) have demonstrated effects of amitraz and BTS-27271 on increasing motility of isolated porcine myometrium. The effect is mediated by an increase in extracellular calcium influx through voltage-dependent calcium channels. Yohimbine again reversed the effects, whereas the alpha-1 antagonist prazosin did not.
Bonsall and Turnbull (17) have suggested that depressor effects of amitraz may be countered by stimulatory effects, depending on the dose administered. In general, high doses may cause depression, whereas low doses may lead to excitatory symptoms such as hyperreactivity to external stimuli and possibly aggressiveness (16) . Because of its known sedative/tranquilizing properties, amitraz administration requires analytical monitoring to regulate its use in performance horses. The purposes of the current study are to investigate the metabolism of amitraz in the horse and develop chromatographic and mass spectrometric methods for its post-administration detection in performance horses.
554
Materials and Methods
Standards
Amitraz was obtained as an analytical standard in free base form from Riedel-de Hai~n (Seelze, Germany) through SigmaAldrich. The N-2,4-dimethylphenyl-N'-methylformamide metabolite was obtained as a 10-ng/pL acetone solution from Dr. Ehrenstorfer GrnbH (Augsburg, Germany). The compound used for this solution was listed as having a 98.5% purity, based on HPLC with W-DAD detection. The compound was also synthesized in free base form in-house, and its spectrometric properties agreed with those of the standard as follows: ESI(+) 
Synthesis of N-(2,4-dimethylphenyl)-N'-methylformamidine and its deuterated analogue
Synthesis of N-(2,4-dimethylphenyl)-N'-methyfformamidine is described only in German patent literature (18) , but procedures for analogous formamidines (19) made it possible to elaborate a preparation of this rnetabolite. N-(2,4-Dimethylphenyl)-N'-methylforrnamidine was synthesized from 2,4-dimethylaniline in a reaction with methylarnine and triethyl orthoformate ( Figure 2 ). Methylamine hydrochloride (1 g, 14.8mM) and triethyl orthoformate (2.19 g, 14.8mM) were first refluxed in 10 mL absolute ethanol for 15 rain, at which point 2,4-dimethylaniline (1.79 g, 14.78mM) in 10 mL absolute ethanol was added dropwise. The addition was complete in 1 h. Following an additional reflux for 30 rain, the reaction mixture was cooled and concentrated in vacuo. The crude product was taken up in water and extracted with dichloromethane. A diluted aqueous solution of NaOH was cautiously added to the aqueous layer until the mixture reached pH 8-9, after which it was extracted with chloroform. The chloroform layer was separated, washed with water, dried (Na2SO4) , and concentrated to a crude crystalline material, which was purified by chromatography on silica gel (ethyl acetate/methanol, 95:5). Yield: 440 mg (18%) (Figure 2 ). The deuterated standard of amitraz metabolite was synthesized similarly using deuterated 2,4-dimethyl-d6-aniline (20) instead of 2,4-dimethylaniline. Reaction of 2,4-dimethyl-d6-aniline (90 mg, 0.55mM) with methylamine hydrochtoride (37.3 rag, 0.55raM) and ethyl orthoformate (81.8 rag, 0.55mM), followed by purification on silica gel column, produced 22 mg
Sample collection
Thoroughbred mares, weighing 450-550 kg, from our dedicated herd were used throughout. Horses were acclimated to their stalls for 24 h prior to drug administrations. All horses were fed twice a day with grass hay and feed (12%), which was a 50:50 mixture of oats and an alfalfa-based protein pellet, and were vaccinated annually for tetanus and dewormed quarterly with ivermectin (MSD Agvet, Rahway, N J). A routine clinical examination was performed before each experiment to ensure that each animal was healthy and sound. During experimentation, each horse was provided water and hay ad libitum. Each mare served as its own control. Animals used in these experiments were managed according to the rules and regulations of the Institutional Animal Care Use Committee at the University of Kentucky, which also approved the experimental protocol. Amitraz (75 rag) was administered intravenously, and urine samples were collected immediately before dose and at 1, 2, 4, 6, 8, and 24 h after administration using a Harris flush tube (24 Fr x 60 in., Seamless, Ocala, FL). Urine samples were divided into aliquots, stored at -20~ until assayed, and then thawed immediately prior to analysis.
Sample preparation for metabolite screens
Metabolite screening involved two methods for ESI(+)-MS direct infusion analysis. In the first, 5-mL urine aliquots were brought to 0.5% NH4OH with 25 pL concentrated NH4OH and extracted twice with 2 mL ethyl acetate (HPLC grade, Fisher, Fairlawn, N J), the organic phases combined and acidified to 0.2% with formic acid (EM Science, Gibbstown, NJ), and immediately examined. In the second method, 1-mL urine aliquots were filtered through a 3000-MW cutoff Centricon-3 filter (Amicon, Inc., a division of Millipore, Beverly, MA) to remove high MW materials. The filters were centrifuged 60 rain at 1000 xg in a type AH-4 swinging bucket rotor in a Beckman (Palo Alto, CA) AccuSpinFR centrifuge. Filtrates were diluted 1:10 with a mixture of 50:50 acetonitrile/0.05% formic acid (aq.) (pH ~ 4) for analysis. In both methods, resultant mixtures were infused 1.2 mL/h via a Harvard (Holliston, MA) syringe pump equipped with a 500-pL Hamilton (Reno, NV) gas-tight syringe. Infusion was direct into the electrospray probe of the Quattro I] MS-MS (Micromass, Beverly, MA).
ESI-MS
Amitraz standards were prepared for direct infusion ESI (positive mode)-MS analysis by dissolution in 0.05% formic acid (aq)/acetonitrile (1:1) to 10 pg/mL. Infusion was carried out with a Harvard syringe pump equipped with a 500-pL Hamilton gastight syringe with infusion at 1.2 mL/h. The mass spectrometer was a Micromass Quattro II ESI-MS-MS, and typical ESI-MS voltage settings for detection and analysis of amitraz were as follows: capillary, 3.02 kV; HV lens, 0.54 kV; cone, 24 kV; skimmer lens, 2.1 kV; RF lens, 0.2 kV; source temperature, 120~ argon pressure for collisionally induced dissociation (CID) experiments, 3-4 x 10 -3 mbar; ionization energies: MS1, 1.0 and MS2, 3.9. Collision energy was set between 10 and 15. ESI-MS and MS-MS spectra were acquired as continuum data fora minimum of 1-2 rain over the m/z 10-800 mass range, applying 1.8 s/scan duration. Resultant data were background subtracted and smoothed with the Micromass MassLynx version 3.4 software. Spectra were deconvoluted with the assistance of Mass Spec Calculator Pro software (version 4.03, Quadtech Associates, Inc., Fairfield, CA).
HPLC methodology for ESI-MS
An Agilent (Atlanta, GA) ]050 HPLC was interfaced with the Quattro II MS-MS and equipped with a Luna phenyl-hexyl 1 x 30-mm, 3-p column (Phenomenex, Torrance, CA). The mobile phase was 52.5% acetonitrile/47.5% deionized water/0.05% formic acid run in isocratic mode at 0.15 mL/min. Multiple re- 
Extraction and derivatization for GC-MS
N-2,4-Dimethylphenyl-N'-methylformamidine was extracted from 1 mL urine in a screw-cap test tube by first introducing 300 n~mLN-2,4-dimethyl-d6-phenyl-N'-methylformamidine as internal standard for quantitation. Then, 6 mL dichloromethane (EM Omnisolv) and 150 pL concentrated NH4OH (~ 30%, w/v) were added, the tube capped and mixed by vortex for 30 s, centrifuged 10 min at 1000 xg in a type AH-4 swinging bucket rotor in a Beckman AccuSpinFR centrifuge, the upper aqueous phase removed and discarded, and the organic phase transferred into a conical tube. Twenty microliters N,Ndimethylformamide (HPLC grade, Aldrich, Milwaukee, WI) was added, and the organic phase was evaporated to near dryness under a stream of N2 in a 35--40~ water bath until just a drop of N,N-dimethylformamide remained. The residue was dissolved in 80 pL MTBSTFA-1% TBDMCS (Pierce Chemicals, Rockville, IL), vortex mixed 5 s, and immediately transferred to a microinjection vial. Derivatization occurred on injection of 1 pL into the GC-MS 250~ injector port.
GC-MS SIM quantitation
GC-MS SIM involved an Agilent 6890/5972 GC-MSD equipped with an HP-5 MS (Agilent) GC column (10 m x 0.25 mm, 0.25-pm film thickness) operated in the splitless mode with 1 mL/min helium. The GC injector was at 250~ the transfer line at 280~ and the oven temperature was programmed as follows: 70~ for 2 rain, then increased to 280~ at 20~ and held at 280~ for 5 rain. SIM data were collected as follows: ions monitored for the tert-butyldimethylsilyl-N-2,4-dimethylphenyl-N'-methyl-formamidine derivative were m/z 278 (M+), 261 (loss of CH3), 219 (loss oft-butyl), and 205 (m/z 261 minus t-butyl), each at a 50 ms dwell; and for the tertbutyldimethylsilyl-N-2,4-dimethyl-@phenyl-N'-methyl-formamidine internal standard, m/z 225 (M+ minus t-butyl) and 208 (m/z 264 loss of methyl minus t-butyl), again at 50 ms dwell. Preparation of the amitraz metabolite calibration curve was accomplished by determining the internal standard (m/z 208) and amitraz (m/z 205) peak areas for a series of standards (0, 2, 5, 10, 50, 100, 300, and 500 ng/mL), calculating the ratio of standard area/internal standard area along the horizontal axis and plotting expected concentrations as a function of this ratio. Standard curves prepared in this fashion provided coefficient of determination r 2 > 0.99. For GC-MS scanning experiments, the m/z 50-700 mass range was scanned at 1.19 scans/s. Figure 3 ). The mass spectrum disclosed two significant peaks at m/z 253 and 163, for which structural interpretations suggest internal rearrangement with loss of CH3CN and cleavage of a C-N bond, respectively, with likely structures included in the figure. These latter peaks are likely MS byproducts of this compound's relative instability. Table I conjugates) with the assumptions that glucuronides form on hydroxyls or carboxylic acids, sulfates form on hydroxyls, and glycine conjugates form on carboxylic acids. This table provided a guide for further analyses. Urinary metabolites were investigated by noting the solubility of amitraz in ethyl acetate, performing a simple ethyl acetate liquid-liquid extraction of post-amitraz dosage equine urine under high pH conditions, and comparing the ESI(+)-MS of 0 and 2 h post-dose samples. suggestive of that of a metabolite. A second approach to potential identification of urinary metabolites involved centrifugal filtration of the urine sample and direct examination of an acidified 1:10 dilution, a method that has previously been successful in identification of glucuronide metabolites (21); however, no candidate Phase II conjugates were identified by either approach. Table II summarizes potential metabolites screened in urine by these methods. The only other possible lead for an equine urinary metabolite was 4-amino-3-methyl-benzoic acid (MW 151, listed in Table I ) and as a likely candidate at M+H m/z 152 in Table II , but this possibility remains to be pursued.
Results
Amitraz was examined by direct infusion ESI(+)-MS and found to give good response as an [M+H] pseudomolecular ion ofm/z 294 (
In Figure 6 , we compare the ESI(+)-MS-MS daughter ion spectra of the m/z 163 metabolite discerned by the Figure 5 comparison of 0 and 2 h samples to a standard of N-2,4-dimethylphenyl-N'-methylformamidine. Their identical appearance supports the proposed structure of the metabolite. The structure is shown as part of Figure 3 and is obtained directly from amitraz in the ESI source because the daughter ion spectrum of the amitraz m/z 163 byproduct (not shown) is also identical to both spectra in Figure 6 . Intact amitraz as am/z 294 ion was, however, not identified during analysis of urine ethyl acetate extracts.
The left-hand panel of Figure 7 presents an HPLC of amitraz with MRM of specific fragmentation events of Figure 4 daughter ion spectrum. The similarity of retention times demonstrates the simultaneity of elution of principle fragmentations. The center panel of Figure 7 compares 0-and 2-h post-dose ethyl acetate extracts run by gradient HPLC with MRM acquisition specific for the m/z 163 amitraz metabolite, disclosing its presence only following amitraz dosing. In the right-hand panel of Figure 7 , the individual fragmentations coincide at the 3.97 RT peak with area ratios corresponding to those of an N-2,4-dimethylphenyl-N'-methylformamidine standard and agreeing with the intensities of the daughter ion spectra of Figure 6 . Demonstration of N-2,4-dimethylphenyl-N'-methylformamidine as the structure of the principal amitraz equine urinary metabolite following oral administration led us to consideration of a deuterated analogue for elaboration of a quantitative confirmatory method. Figure 8 shows the ESI(+)-MS-MS daughter ion spectrum of a d6 metabolite m/z 169 M+H ion, and Table III includes a comparative interpretation of the d6 and do metabolite fragment ions. However, quantitation of the m/z 163 ion was hampered by a severe reduction in sensitivity by the LC-MS-MS method. GC-MS was considered a viable alternative approach, and Figure 9 describes the results obtained with two methods of N-2,4-dimethylphenyl-N'-methylformamidine silylation. The two methods gave similar results in terms of good chromatographic peak shape and reasonable mass spectra capable of providing characteristic high MW ions of good intensity for generation of SIM methods including quantitative and qualitative ions data acquisition. However, work directed towards defining instrument linearity quickly disclosed that the TMS derivative ( Figure 9A and 9B) was inferior to the tBuDMS derivative ( Figure 9C and 9D) in terms of sensitivity and linearity, primarily due to matrix interference with TMS derivative-specific ions; matrix components may interfere to some extent with formation of the TMS derivative but interfere in a more serious manner by chromatographic coelution. When it became clear that the tBuDMS derivative provided significant advantages, this silylation method was applied to the d6 internal standard, with results as described in Figure 10 . As with the do compound in Figure 9C , extracted ion chromatography here also disclosed appropriate ions for quantitative and qualitative purposes (mlz 208, 225, and 282) (Figure 10A) . The mass spectrum in Figure 10B shows displacement of the do analogue rule 219 ion ( Figure 9D) ions, respectively) of an extracted 0 ng/mL standard, showed a measurable but slight amount of the do compound present in the d~-internal standard, to the extent of 0.3%. However, this did not interfere with generation of the calibration curve, and extraction from spiked horse urine allowed generation of a linear calibration curve as presented in Figure 11 . Figure 12A illustrates ion chromatograms acquired from the extract ofa l-mL urine sample 1 h post dose and specifically indicating the location of coeluting quantifier (rnlz 205) and qual- ifier ions (m/z 219, 261, and 276). The urine concentration of metabolite based on m/z 205 was 8.2 ng/mL. Figure 12B demonstrates measurements taken to determine peak height and noise height for m/z 219 for assurance that the S/N ratio had not fallen below the limit of 3. Finally, Figure 12C shows the time course of changes in urinary concentrations of N-2,4-dimethylphenyl-N'-methylformamidine in urine following dosage with 75 mg amitraz (i.v.). Only two points exceeded the LOD of the assay, indicating the rapidity with which elimination of this particular metabolite occurs in the horse. Validation information for the amitraz metabolite GC-MS confirmatory method is as follows. Standard curves showed a linear response between 2 and 300 ng/mL with a coefficient of determination r 2 > 0.99. Extraction efficiency for the SPE method ranged between 75-83% for the analyte spiked into urine. For the instrument lower LOD, S/N ratios were recorded for decreasing amounts of tertbutyldimethylsilyl-N-2, 4-dimethylphenyl-N '-methyl-formamidine, and the ratio fell below a limit of 3 at 50 pg (measured as underivatized metabolite) on column for two of the four principal SIM ions (m/z 261 and 276), corresponding roughly to a 5 ng/mL sample. The lower LOD in urine was determined by following the ion ratios to decreasing levels and determining whether ratios were maintained within Association of Official Racing Chemists minimum criteria (Proposed guidelines released 2001), namely 5% absolute or 30% relative for low resolution SIM. Measurements exceeded these criteria at a 50 pg injection, corresponding to a 5 ng/mL sample. Recovery of N-2,4-dimethylphenyl-N'-methyl-formamidine during assays performed over three runs on different days provided an average measurement of 20.03 ng/mL with an average cv of 9.2% for a 20 ng/mL low standard and 291.7 ng/mL with an average CV of 7.4% for a 300-ng/mL high standard.
Table III. Principal ESI(+)-MS-MS Daughter Ions of N-(2,4-dimethylphenyl)-N'-Methylformamidine and Their Interpretation in Comparison to
Specificity of the assay was tested by GC-MS confirmation analysis of unextracted standards of the structurally related alpha2-agonists guanabenz, guanfacine, guanethidine, and guanadrel; the structurally related antiulcer medication cimetidine; and furosemide and phenylbutazone, two therapeutic medications widely used in equine medicine (W. Carter, personal communication). None of the tBuDMS-derivatives coeluted with that of N-2,4-dimethylphenyl-N'-methyl formamide, with retention times relative to tertbutyldimethylsilyl-N-2, 4-dimethylphenyl-N '-methyl-formamidine as follows: guanethidine, four peaks at -1.99, -1.69, -1.37, and +0.07 rain; guanabenz, four peaks at -0.89, -0.80, +0.36, and +2.87 rain; guanfacine, three peaks at +0.29, +1.47, and +2.88 rain; guanadrel, two peaks at +0.25 and +2.39 rain; cimetidine, three peaks at +2.60, +3.03, and +4.46 rain; phenylbutazone-tBuDMS, +4.86 min; and furosemide, two peaks at +7.05 and +9.64 rain. When these drugs were present at the equivalent of 100 ng/mL, no effect was observed on quantitation of the amitraz metabolite at concentrations of 50 or 500 ng/mL or even at the LOD of 5 ng/mL. Ion ratios m/z 276/205 and 219/205 for the amitraz-d0 compound and 282/208 and 225/208 for the d6 internal standard were unaffected, and there was no effect on their respective retention times. When the compounds were added to blank serum at concentrations of 500 ng/mL, extracted, and analyzed, no chromatographic interference was observed (i.e., no coeluting interference was observed in specific ion chromatograms for m/z 208, 205, 276, or 219).
Discussion
Amitraz is known to possess characteristic sedative and tranquilizing properties in the horse and other species, principally due to its alpha-2 adrenergic agonist characteristics. As such, regulatory control of the use of amitraz in performance horses requires the availability of analytical monitoring techniques to (11) . These investigators reported distribution half-lives of 1.98 rain for amitraz and 2.17 rain for BTS 27271 (derived from amitraz) in ponies, following 1 mg/kg i.v. doses; elimination half-lives were significantly greater at 39.4 and 44.2 rain, respectively. These doses were significantly greater than those utilized in the study reported here and resulted in a slow onset of sedation, which reached a maximum effect 10-15 rain following injection. Although our purpose was not to measure pharmacological effect but metabolism, the 75-mg i.v. dose (roughly 0.15 mg/kg) nonetheless produced sedative effects in our horses (see also reference 14). The pharmacokinetic parameters for amitraz and BTS 27271 measured by Pass and Mogg (11) were comparable to those of the alpha-2 agonist xylazine (0.6 mg/kg i.v.), with a measured distribution half-life of 5.9 min and elimination half-life of 50 min in the horse (22) . Such pharmacokinetic parameters are typically measured within 120 min following i.v. dose (11, 22) , because of the rapid decline in blood levels of these agents. Whereas it is our intention to guide laboratories in the development of methodologies for the confirmation of amitraz, the agent's rapid turnover suggests that if control of this agent is to be regulated by examination of the N-2,4-dimethylphenyl-N'-methylformamidine metabolite as described herein, then the urine samples must optimally be taken within 2 h of the time of administration of this agent.
